

DAFTAR PUSTAKA

1. Carretero C. Peptic ulcer disease. *Med.* 2016;12(3):111–117.
2. Garrow D, Delegge MH. Risk factors for gastrointestinal ulcer disease in the US population. *Dig Dis Sci.* 2010;55(1):66–72.
3. Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. *BMC Gastroenterol.* 2022;22(1):1–13.
4. Laine L. Review article: The effect of *Helicobacter pylori* infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. *Aliment Pharmacol Ther Suppl.* 2002;16(1):34–39.
5. Talebi Bezmin Abadi A. Diagnosis of *Helicobacter pylori* Using Invasive and Noninvasive Approaches. *J Pathog.* 2018;2018:9064952. doi:10.1155/2018/9064952
6. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current Perspectives in NSAID-Induced Gastropathy. 2013;2013. doi:10.1155/2013/258209
7. Hawkins C, Hanks GW. The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs. A review of the literature. *J Pain Symptom Manage.* 2000;20(2):140–151. doi:10.1016/S0885-3924(00)00175-5
8. Zhang W, Liang X, Chen X, Ge Z, Lu H. Time trends in the prevalence of *Helicobacter pylori* infection in patients with peptic ulcer disease: a single-center retrospective study in Shanghai. *J Int Med Res.* 2021;49(10). doi:10.1177/030006052110511
9. Miftahussurur M, Waskito LA, Fauzia KA, и съавт. Overview of *helicobacter pylori* infection in indonesia: what distinguishes it from countries with high gastric cancer incidence? *Gut Liver.* 2021;15(5):653–665.
10. Arroyo MT, Forne M, De Argila CM, и съавт. The prevalence of peptic ulcer not related to *Helicobacter pylori* or non-steroidal anti-inflammatory

- drug use is negligible in Southern Europe. *Helicobacter*. 2004;9(3):249–254. doi:10.1111/j.1083-4389.2004.00219.x
11. Nagata N, Niikura R, Sekine K, и съавт. Risk of peptic ulcer bleeding associated with *Helicobacter pylori* infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs: A case-control study. *J Gastroenterol Hepatol*. 2015;30(2):292–298.
 12. Malfertheiner P, Chan FK, McColl K EL. Peptic ulcer disease. *Lancet*. 2009;374(9699):1449–1461. doi:10.1016/S0140-6736(09)60938-7
 13. Milosavljevic T, Kostić-Milosavljević M, Jovanović I, Krstić M. Complications of peptic ulcer disease. *Dig Dis*. 2011;29(5):491–493.
 14. Athalia Nofera Kurniawan, Riki Tenggara, Lucky Hartati Moehario. Deteksi Antigen *Helicobacter pylori* Pada Pasien GERD dan Non-GERD di Rumah Sakit Atma Jaya. *J Indones Med Assoc*. 2020;69(8):252–257.
 15. Sudoyo A, Simadibrata M, Setiyohadi B, Af S, Ilmu A, Dalam P. Rani A, Fauzi A. Infeksi *Helicobacter Pylori* dan Penyakit Gastroduodenal. In: Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setiyohadi B, Syam AF, eds. *Buku Ajar Ilmu Penyakit Dalam . VI*. Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; 2014:1772. Published online 2014:2014.
 16. Brzozowski T, Konturek PC, Śliwowski Z, и съавт. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with *Helicobacter pylori* in the stomach of humans and experimental animals. *J Physiol Pharmacol*. 2006;57(SUPPL. 3):67–79.
 17. Zapata-Colindres JC, Zepeda-Gómez S, Montaña-Loza A, Vásquez-Ballesteros E, de Jesús Villalobos J, Valdovinos-Andraca F. The association of *Helicobacter pylori* infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. *Can J Gastroenterol*. 2006;20(4):277–280.
 18. Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: The role of *Helicobacter pylori*. *Gastroenterology*. 1992;102(6):1899–

1905.

19. Djumhana, Hadi S, Abdurachman SA, Widjojo J, Saketi JR. Prevalences of helicobacter pylori among nsaid users and non-users. *J Gastroenterol Hepatol*. 2000;15(12):H3–H3. doi:10.1046/j.1440-1746.2000.000a9.x
20. Hamid S, Yakoob J, Jafri W, Islam S, Abid S, Islam M. Frequency of NSAID induced peptic ulcer disease. *J Pakistan Med Assoc*. 2006;56(5):218.
21. Kim HK, Kim JI, Kim JK, и съавт. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. *Dig Dis Sci*. 2007;52:1776–1782.
22. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. *Lancet*. 2002;359(9300):14–22.
23. Papatheodoridis G V, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. *Clin Gastroenterol Hepatol*. 2006;4(2):130–142.